Therapeutic Role and Immunogenic Characteristics of Cancer Testis Antigens in Breast Cancer: A Review.

IF 2 4区 生物学 Q4 CELL BIOLOGY
Motahareh Sheikh-Hosseini, Mostafa Neissi, Mohammad Moarefzadeh, Mahdieh Salimi, Azar Heidarizadi, Fateme Mohammadi-Asl
{"title":"Therapeutic Role and Immunogenic Characteristics of Cancer Testis Antigens in Breast Cancer: A Review.","authors":"Motahareh Sheikh-Hosseini, Mostafa Neissi, Mohammad Moarefzadeh, Mahdieh Salimi, Azar Heidarizadi, Fateme Mohammadi-Asl","doi":"10.22074/cellj.2026.2044248.1703","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer remains a leading cause of cancer-related deaths among women globally, presenting significant challenges due to its heterogeneity and complex biology. While traditional treatments such as surgery, chemotherapy, and targeted therapies offer some benefit, the lack of universal treatment strategies underscores the need for innovative approaches. A total of 255 articles were identified through PubMed, Scopus, Web of Science, and Google Scholar up to 1 December 2025, and 30 articles were selected for inclusion in this narrative review. This narrative review focuses on cancer-testis antigens (CTAs) as potential therapeutic targets in breast cancer. The objective of this narrative review is to evaluate the therapeutic role and immunogenic characteristics of CTAs in breast cancer, with emphasis on their potential in diagnosis, prognosis, and immunotherapy. CTAs are tumor-associated antigens that are aberrantly expressed in various cancers, including breast cancer, while their expression in normal tissues is restricted to the testis. Their unique immunogenic properties make them ideal candidates for both early diagnostic tools and targeted immunotherapy. This article discusses the potential of CTAs in improving breast cancer screening, prognosis, and treatment strategies, with particular emphasis on their roles in immunotherapy and vaccine development. Furthermore, the challenges of CTA-based treatments, including antigen heterogeneity and immune evasion, are outlined, along with insights into future research directions aimed at overcoming these obstacles and improving clinical outcomes.</p>","PeriodicalId":49224,"journal":{"name":"Cell Journal","volume":"27 1","pages":"1-13"},"PeriodicalIF":2.0000,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Journal","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.22074/cellj.2026.2044248.1703","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Breast cancer remains a leading cause of cancer-related deaths among women globally, presenting significant challenges due to its heterogeneity and complex biology. While traditional treatments such as surgery, chemotherapy, and targeted therapies offer some benefit, the lack of universal treatment strategies underscores the need for innovative approaches. A total of 255 articles were identified through PubMed, Scopus, Web of Science, and Google Scholar up to 1 December 2025, and 30 articles were selected for inclusion in this narrative review. This narrative review focuses on cancer-testis antigens (CTAs) as potential therapeutic targets in breast cancer. The objective of this narrative review is to evaluate the therapeutic role and immunogenic characteristics of CTAs in breast cancer, with emphasis on their potential in diagnosis, prognosis, and immunotherapy. CTAs are tumor-associated antigens that are aberrantly expressed in various cancers, including breast cancer, while their expression in normal tissues is restricted to the testis. Their unique immunogenic properties make them ideal candidates for both early diagnostic tools and targeted immunotherapy. This article discusses the potential of CTAs in improving breast cancer screening, prognosis, and treatment strategies, with particular emphasis on their roles in immunotherapy and vaccine development. Furthermore, the challenges of CTA-based treatments, including antigen heterogeneity and immune evasion, are outlined, along with insights into future research directions aimed at overcoming these obstacles and improving clinical outcomes.

癌睾丸抗原在乳腺癌中的治疗作用及免疫原性研究进展。
乳腺癌仍然是全球妇女癌症相关死亡的主要原因,由于其异质性和复杂的生物学特性,提出了重大挑战。虽然手术、化疗和靶向治疗等传统治疗方法提供了一些益处,但缺乏普遍的治疗策略强调了创新方法的必要性。截至2025年12月1日,通过PubMed、Scopus、Web of Science和b谷歌Scholar共识别了255篇文章,其中30篇文章被选中纳入本叙述性综述。本文综述了癌睾丸抗原(cta)作为乳腺癌潜在治疗靶点的研究进展。这篇叙述性综述的目的是评估cta在乳腺癌中的治疗作用和免疫原性特征,重点是它们在诊断、预后和免疫治疗方面的潜力。cta是肿瘤相关抗原,在包括乳腺癌在内的各种癌症中异常表达,而它们在正常组织中的表达仅限于睾丸。它们独特的免疫原性使其成为早期诊断工具和靶向免疫治疗的理想候选者。本文讨论了cta在改善乳腺癌筛查、预后和治疗策略方面的潜力,特别强调了它们在免疫治疗和疫苗开发中的作用。此外,还概述了基于cta治疗的挑战,包括抗原异质性和免疫逃避,以及旨在克服这些障碍和改善临床结果的未来研究方向的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cell Journal
Cell Journal CELL BIOLOGY-
CiteScore
3.40
自引率
5.00%
发文量
0
审稿时长
12 months
期刊介绍: The “Cell Journal (Yakhteh)“, formerly published as “Yakhteh Medical Journal”, is a quarterly English publication of Royan Institute. This journal focuses on topics relevant to cellular and molecular scientific areas, besides other related fields. The Cell J has been certified by Ministry of Culture and Islamic Guidance in 1999 and was accredited as a scientific and research journal by HBI (Health and Biomedical Information) Journal Accreditation Commission in 2000 which is an open access journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书